在国家政策对创新药的大力支持下，我国已有多款BTK抑制剂成功上市并纳入医保目录。截至目前，国 家医保目录纳入了多款BTK抑制剂，其中包括奥布替尼片、阿可替尼胶囊/马来酸阿可替尼片、匹妥布 替尼片等。今年，马来酸阿可替尼片用于CLL/SLLL（慢性淋巴细胞白血病/小淋巴细胞淋巴瘤）等适应 证被正式纳入医保，加之其他药物的成功续约，实现该类血液肿瘤多个疾病阶段的医保覆盖。 科技日报记者 张佳星 12月7日，国家医疗保障局正式公布2025年《国家基本医疗保险、生育保险和工伤保险药品目录》（以 下简称医保目录）。本次调整新增114种药品，目录内药品总数增至3253种，覆盖肿瘤、慢性病、罕见 病等多个治疗领域。肿瘤领域中的马来酸阿可替尼片等多款血液肿瘤新药被纳入。 哈尔滨血液病肿瘤研究所所长、中国临床肿瘤学会监事会监事长马军教授表示，对于慢性淋巴细胞白血 病、套细胞淋巴瘤等血液肿瘤患者来说，避免复发、延长无进展生存期是控制疾病关键。然而，淋巴瘤 临床诊疗长期面临着传统药物安全性不足、易复发、老年患者治疗棘手、与抗酸药等联用兼容性差等痛 点。 随着医学研究的深入发展，布鲁顿氏酪氨酸激酶（BTK）抑制剂等新型靶向药物问世， ...

Core Insights - Guangdong Province has approved a list of 107 innovative drug and medical device products, including 46 innovative drugs, to enhance the application of these products in public medical institutions [1][5] - Among the approved innovative drugs, 10 are anti-cancer drugs, representing 22% of the total, showcasing Guangdong's strength in cancer treatment research and manufacturing [3][5] Summary by Category Innovative Drug List - The list includes 107 innovative products, with 46 classified as innovative drugs [1] - The anti-cancer drugs cover various prevalent malignant tumors, indicating significant research capabilities in this area [3] Anti-Cancer Drugs - The 10 anti-cancer drugs listed include: - Aorebatinib for chronic myeloid leukemia - Sapalizumab for cervical cancer and Hodgkin lymphoma - Socazolimab for cervical cancer - Sidabenzamide for diffuse large B-cell lymphoma - Cardunilimab for cervical cancer and gastric adenocarcinoma - Acetate injection for prostate cancer - Trelizumab for multiple cancers including Hodgkin lymphoma and non-small cell lung cancer - Panitumumab for multiple cancers including non-small cell lung cancer - Obinutuzumab for adult lymphomas - Ivorilumab for lung cancer [4] Industry Development - Guangdong pharmaceutical companies are accelerating their internationalization, exemplified by the approval of Panitumumab for the U.S. market [5] - The integration of industry, academia, and research has been pivotal in the development of these innovative drugs, with local scholars leading significant research efforts [5] - The comprehensive innovation capability from research to clinical application is being established, enhancing Guangdong's competitive edge in the global biopharmaceutical industry [5]